^
    Back
    Association details:
    Biomarker:TA-MUC1 elevation + EGFR expression
    Cancer:Head and Neck Cancer
    Drug:PankoMab-GEX (gatipotuzumab) (MUC1 inhibitor) +
    CetuGEX (tomuzotuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO Open
    Title:

    Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

    Published date:
    04/06/2022
    Excerpt:
    Patients received gatipotuzumab administered at 1400 mg every 2 weeks, 6 weeks after the start of the glyco-optimized anti-EGFR antibody tomuzotuximab at 1200 mg every 2 weeks. As this regimen was proven safe, enrollment continued in an expansion phase (EP) of patients with refractory metastatic colorectal cancer, non-small-cell lung cancer, head and neck cancer and breast cancer....In the EP, patients with baseline sTA-MUC1 levels above the median appeared to have improved progression-free survival and overall survival.
    DOI:
    10.1016/j.esmoop.2022.100447
    Trial ID:
    GATTO